Concepts (243)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 14 | 2018 | 375 | 1.520 |
Why?
|
| Sarcoma, Kaposi | 1 | 2018 | 25 | 0.610 |
Why?
|
| Vascular Neoplasms | 1 | 2018 | 15 | 0.610 |
Why?
|
| Hemangiosarcoma | 1 | 2018 | 23 | 0.600 |
Why?
|
| Dissection | 1 | 2018 | 29 | 0.600 |
Why?
|
| Breast Neoplasms | 12 | 2018 | 1536 | 0.590 |
Why?
|
| Hemangioma | 1 | 2018 | 51 | 0.590 |
Why?
|
| Radiation Exposure | 1 | 2018 | 84 | 0.550 |
Why?
|
| Leukemia, Prolymphocytic, T-Cell | 1 | 2013 | 3 | 0.440 |
Why?
|
| Diagnosis, Differential | 10 | 2018 | 1140 | 0.380 |
Why?
|
| Lymph Nodes | 8 | 2010 | 258 | 0.320 |
Why?
|
| Doxorubicin | 2 | 2006 | 231 | 0.300 |
Why?
|
| Skin | 3 | 2018 | 451 | 0.280 |
Why?
|
| Drug Eruptions | 1 | 2006 | 16 | 0.270 |
Why?
|
| Histiocytic Sarcoma | 1 | 2006 | 3 | 0.270 |
Why?
|
| Langerhans Cells | 1 | 2006 | 10 | 0.270 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2006 | 12 | 0.270 |
Why?
|
| Melanoma | 3 | 2018 | 335 | 0.260 |
Why?
|
| Sarcoma | 1 | 2006 | 70 | 0.260 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2005 | 12 | 0.250 |
Why?
|
| Carcinoma in Situ | 1 | 2005 | 47 | 0.240 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2005 | 46 | 0.240 |
Why?
|
| Synovial Membrane | 2 | 1994 | 23 | 0.240 |
Why?
|
| Mammaplasty | 2 | 1994 | 41 | 0.230 |
Why?
|
| Skin Diseases | 3 | 2010 | 122 | 0.220 |
Why?
|
| Breast | 2 | 1994 | 137 | 0.220 |
Why?
|
| Prostheses and Implants | 2 | 1994 | 159 | 0.210 |
Why?
|
| Axilla | 5 | 2018 | 36 | 0.210 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2005 | 629 | 0.190 |
Why?
|
| Humans | 39 | 2018 | 68618 | 0.170 |
Why?
|
| Biopsy | 6 | 2013 | 540 | 0.170 |
Why?
|
| Nevus | 1 | 1999 | 17 | 0.160 |
Why?
|
| Epidermis | 3 | 2006 | 42 | 0.160 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2018 | 114 | 0.150 |
Why?
|
| Foreign-Body Reaction | 2 | 1994 | 24 | 0.150 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2018 | 79 | 0.150 |
Why?
|
| Nevus, Blue | 1 | 2016 | 3 | 0.140 |
Why?
|
| Aged | 9 | 2018 | 14862 | 0.140 |
Why?
|
| Fatal Outcome | 2 | 2014 | 164 | 0.130 |
Why?
|
| Inclusion Bodies | 1 | 1996 | 10 | 0.130 |
Why?
|
| Porphyria Cutanea Tarda | 1 | 1996 | 4 | 0.130 |
Why?
|
| Colloids | 1 | 1996 | 43 | 0.130 |
Why?
|
| Antiporters | 1 | 1995 | 5 | 0.130 |
Why?
|
| Eccrine Glands | 1 | 1995 | 3 | 0.130 |
Why?
|
| Granuloma Annulare | 1 | 1995 | 4 | 0.130 |
Why?
|
| Epidermal Cyst | 1 | 1995 | 3 | 0.130 |
Why?
|
| Scalp Dermatoses | 1 | 1995 | 13 | 0.130 |
Why?
|
| Dermatitis Herpetiformis | 1 | 1995 | 3 | 0.130 |
Why?
|
| Female | 22 | 2018 | 38074 | 0.120 |
Why?
|
| Panniculitis | 2 | 1995 | 7 | 0.120 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2014 | 10 | 0.120 |
Why?
|
| Sweat Gland Neoplasms | 2 | 1995 | 16 | 0.120 |
Why?
|
| Male | 19 | 2018 | 37321 | 0.120 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2014 | 79 | 0.120 |
Why?
|
| Biomarkers, Tumor | 3 | 2010 | 508 | 0.110 |
Why?
|
| Metaplasia | 4 | 1995 | 27 | 0.110 |
Why?
|
| Cell Nucleus | 1 | 1995 | 305 | 0.110 |
Why?
|
| Middle Aged | 18 | 2010 | 21147 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 151 | 0.110 |
Why?
|
| Immunohistochemistry | 5 | 2018 | 1174 | 0.110 |
Why?
|
| Lymphatic Metastasis | 6 | 2010 | 274 | 0.110 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2005 | 53 | 0.110 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 234 | 0.100 |
Why?
|
| Fibroma | 1 | 1991 | 20 | 0.100 |
Why?
|
| Carcinoma, Ductal | 1 | 2010 | 14 | 0.090 |
Why?
|
| Carcinoma, Lobular | 1 | 2010 | 20 | 0.090 |
Why?
|
| Pyoderma | 1 | 1990 | 2 | 0.090 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2010 | 37 | 0.090 |
Why?
|
| Dermatomycoses | 1 | 1989 | 17 | 0.090 |
Why?
|
| Granuloma | 1 | 1989 | 21 | 0.090 |
Why?
|
| Cryptococcosis | 1 | 1989 | 28 | 0.090 |
Why?
|
| Adult | 11 | 2014 | 21403 | 0.090 |
Why?
|
| Carcinoma, Basal Cell | 1 | 1989 | 40 | 0.090 |
Why?
|
| Neoplasm Proteins | 2 | 2005 | 307 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 3 | 2010 | 369 | 0.080 |
Why?
|
| Adenoma | 1 | 1990 | 132 | 0.080 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 1988 | 15 | 0.080 |
Why?
|
| B-Lymphocytes | 1 | 2010 | 329 | 0.080 |
Why?
|
| Acetylglucosamine | 2 | 1999 | 46 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2010 | 446 | 0.070 |
Why?
|
| Neoplasm Staging | 6 | 2010 | 800 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2010 | 710 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 2 | 1998 | 492 | 0.070 |
Why?
|
| Scleromyxedema | 1 | 2006 | 1 | 0.070 |
Why?
|
| Paresthesia | 1 | 2006 | 8 | 0.070 |
Why?
|
| Burkitt Lymphoma | 1 | 2006 | 18 | 0.070 |
Why?
|
| Hand Dermatoses | 1 | 2006 | 10 | 0.070 |
Why?
|
| Ifosfamide | 1 | 2006 | 5 | 0.070 |
Why?
|
| Foot Dermatoses | 1 | 2006 | 12 | 0.070 |
Why?
|
| Erythema | 1 | 2006 | 18 | 0.070 |
Why?
|
| Exanthema | 1 | 2006 | 30 | 0.070 |
Why?
|
| Remission Induction | 1 | 2006 | 111 | 0.070 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2006 | 62 | 0.070 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2006 | 57 | 0.070 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2006 | 82 | 0.060 |
Why?
|
| Uteroglobin | 1 | 2005 | 5 | 0.060 |
Why?
|
| Drug Carriers | 1 | 2006 | 90 | 0.060 |
Why?
|
| Liposomes | 1 | 2006 | 107 | 0.060 |
Why?
|
| Polyethylene Glycols | 1 | 2006 | 149 | 0.060 |
Why?
|
| Disease-Free Survival | 1 | 2006 | 349 | 0.060 |
Why?
|
| Biomarkers | 1 | 1990 | 1593 | 0.060 |
Why?
|
| Pancreatic Neoplasms | 3 | 1996 | 332 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2005 | 320 | 0.060 |
Why?
|
| Palliative Care | 1 | 2006 | 271 | 0.060 |
Why?
|
| Carcinoembryonic Antigen | 2 | 1995 | 17 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2005 | 498 | 0.050 |
Why?
|
| Polysaccharides | 2 | 1999 | 176 | 0.040 |
Why?
|
| Hemostatics | 1 | 1999 | 47 | 0.040 |
Why?
|
| Prognosis | 4 | 2010 | 2093 | 0.040 |
Why?
|
| Tissue Array Analysis | 1 | 2018 | 53 | 0.040 |
Why?
|
| Heterografts | 1 | 2018 | 70 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2018 | 294 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2018 | 241 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 2 | 1994 | 196 | 0.040 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1997 | 101 | 0.040 |
Why?
|
| Cancer Vaccines | 1 | 1997 | 61 | 0.040 |
Why?
|
| Lymph Node Excision | 3 | 2004 | 91 | 0.040 |
Why?
|
| Melanocytes | 1 | 1996 | 23 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2010 | 2358 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 1997 | 132 | 0.030 |
Why?
|
| Pancreatic Cyst | 1 | 1996 | 16 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2018 | 447 | 0.030 |
Why?
|
| Nevus, Pigmented | 1 | 1996 | 30 | 0.030 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 1996 | 22 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2018 | 434 | 0.030 |
Why?
|
| Transfection | 1 | 2018 | 782 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2010 | 3259 | 0.030 |
Why?
|
| Medical Records | 1 | 1996 | 121 | 0.030 |
Why?
|
| Basement Membrane | 1 | 1996 | 48 | 0.030 |
Why?
|
| Keratinocytes | 1 | 1996 | 68 | 0.030 |
Why?
|
| Pyoderma Gangrenosum | 1 | 1995 | 7 | 0.030 |
Why?
|
| Hyperplasia | 1 | 1995 | 89 | 0.030 |
Why?
|
| Skin Ulcer | 1 | 1995 | 19 | 0.030 |
Why?
|
| Elastic Tissue | 1 | 1995 | 28 | 0.030 |
Why?
|
| Fibrin | 1 | 1995 | 35 | 0.030 |
Why?
|
| Bowen's Disease | 1 | 1994 | 6 | 0.030 |
Why?
|
| Blister | 1 | 1995 | 16 | 0.030 |
Why?
|
| Abscess | 1 | 1995 | 37 | 0.030 |
Why?
|
| Sensitivity and Specificity | 3 | 2005 | 1753 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 1997 | 483 | 0.030 |
Why?
|
| Fibrinogen | 1 | 1995 | 87 | 0.030 |
Why?
|
| Edema | 1 | 1995 | 66 | 0.030 |
Why?
|
| Adalimumab | 1 | 2014 | 16 | 0.030 |
Why?
|
| Immunoglobulin A | 1 | 1995 | 79 | 0.030 |
Why?
|
| Fasciitis | 1 | 1994 | 30 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2018 | 2550 | 0.030 |
Why?
|
| Surgery, Plastic | 1 | 1994 | 14 | 0.030 |
Why?
|
| Cyclosporine | 1 | 1994 | 121 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 1994 | 149 | 0.030 |
Why?
|
| Occupational Diseases | 1 | 1994 | 68 | 0.030 |
Why?
|
| Eosinophilia | 1 | 1994 | 47 | 0.030 |
Why?
|
| Trichloroethylene | 1 | 1994 | 41 | 0.030 |
Why?
|
| Head and Neck Neoplasms | 2 | 1991 | 561 | 0.030 |
Why?
|
| Psoriasis | 1 | 2014 | 46 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2018 | 1034 | 0.030 |
Why?
|
| Neutrophils | 1 | 1995 | 204 | 0.030 |
Why?
|
| Microscopy, Electron | 1 | 1994 | 351 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 1851 | 0.030 |
Why?
|
| Graft vs Host Disease | 1 | 1994 | 163 | 0.030 |
Why?
|
| Neoplasm Metastasis | 2 | 2005 | 306 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 2010 | 1664 | 0.030 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 1991 | 6 | 0.020 |
Why?
|
| Forearm | 1 | 1991 | 25 | 0.020 |
Why?
|
| Sclerosis | 1 | 1991 | 32 | 0.020 |
Why?
|
| Vimentin | 1 | 1991 | 47 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 1995 | 617 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 1994 | 511 | 0.020 |
Why?
|
| Pseudolymphoma | 1 | 2010 | 6 | 0.020 |
Why?
|
| Anemia, Pernicious | 1 | 1990 | 11 | 0.020 |
Why?
|
| Chronic Disease | 3 | 1990 | 1330 | 0.020 |
Why?
|
| Carcinoid Tumor | 1 | 1990 | 20 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2010 | 3705 | 0.020 |
Why?
|
| S100 Proteins | 1 | 1990 | 42 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 1990 | 114 | 0.020 |
Why?
|
| Pancreatitis | 2 | 1990 | 279 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 1991 | 201 | 0.020 |
Why?
|
| Mice | 2 | 2018 | 8474 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2004 | 1465 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 1988 | 144 | 0.020 |
Why?
|
| Collagen | 1 | 1991 | 636 | 0.020 |
Why?
|
| Animals | 3 | 2018 | 20881 | 0.020 |
Why?
|
| Karyotyping | 1 | 2006 | 74 | 0.020 |
Why?
|
| Fibroblasts | 1 | 1991 | 902 | 0.020 |
Why?
|
| Trefoil Factor-1 | 1 | 2005 | 2 | 0.020 |
Why?
|
| Mammaglobin A | 1 | 2005 | 4 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2005 | 168 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 1988 | 475 | 0.020 |
Why?
|
| Fibrosis | 1 | 2006 | 371 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2004 | 76 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2005 | 194 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 2006 | 307 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 191 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 1996 | 7277 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2005 | 737 | 0.010 |
Why?
|
| Reference Values | 1 | 2004 | 579 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2004 | 714 | 0.010 |
Why?
|
| Computer Systems | 1 | 2001 | 42 | 0.010 |
Why?
|
| Proteins | 1 | 2005 | 474 | 0.010 |
Why?
|
| Reference Standards | 1 | 2001 | 115 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2010 | 4848 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2001 | 251 | 0.010 |
Why?
|
| DNA Primers | 1 | 2001 | 302 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2004 | 1553 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2005 | 2077 | 0.010 |
Why?
|
| Digestive System Surgical Procedures | 1 | 1999 | 30 | 0.010 |
Why?
|
| Hemostatic Techniques | 1 | 1999 | 23 | 0.010 |
Why?
|
| Base Sequence | 1 | 2001 | 1015 | 0.010 |
Why?
|
| Administration, Topical | 1 | 1999 | 111 | 0.010 |
Why?
|
| Acetylation | 1 | 1999 | 94 | 0.010 |
Why?
|
| Postoperative Hemorrhage | 1 | 1999 | 69 | 0.010 |
Why?
|
| Intestine, Small | 1 | 1999 | 89 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2001 | 1447 | 0.010 |
Why?
|
| Spleen | 1 | 1999 | 301 | 0.010 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 1998 | 11 | 0.010 |
Why?
|
| Mastectomy, Modified Radical | 1 | 1998 | 6 | 0.010 |
Why?
|
| Breast Neoplasms, Male | 1 | 1998 | 12 | 0.010 |
Why?
|
| Keratins | 1 | 1998 | 48 | 0.010 |
Why?
|
| Mastectomy, Segmental | 1 | 1998 | 64 | 0.010 |
Why?
|
| Swine | 1 | 1999 | 672 | 0.010 |
Why?
|
| MART-1 Antigen | 1 | 1997 | 10 | 0.010 |
Why?
|
| Jurkat Cells | 1 | 1997 | 59 | 0.010 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1999 | 185 | 0.010 |
Why?
|
| Delayed-Action Preparations | 1 | 1997 | 120 | 0.010 |
Why?
|
| Logistic Models | 1 | 2001 | 1420 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 1998 | 504 | 0.010 |
Why?
|
| Pilot Projects | 1 | 1999 | 1342 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1997 | 742 | 0.010 |
Why?
|
| Biocompatible Materials | 1 | 1997 | 247 | 0.010 |
Why?
|
| Physical Phenomena | 1 | 1994 | 10 | 0.010 |
Why?
|
| Physics | 1 | 1994 | 9 | 0.010 |
Why?
|
| Fibrocystic Breast Disease | 1 | 1994 | 7 | 0.010 |
Why?
|
| Cross Reactions | 1 | 1994 | 57 | 0.010 |
Why?
|
| Cytokines | 1 | 1997 | 866 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 2 | 1996 | 2324 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 1998 | 1851 | 0.010 |
Why?
|
| Environmental Exposure | 1 | 1994 | 269 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 1997 | 2791 | 0.010 |
Why?
|
| Octreotide | 1 | 1990 | 21 | 0.010 |
Why?
|
| Scleroderma, Systemic | 1 | 1994 | 446 | 0.010 |
Why?
|
| Stomach Neoplasms | 1 | 1990 | 64 | 0.010 |
Why?
|
| Pancreatic Ducts | 1 | 1988 | 76 | 0.000 |
Why?
|
| Acute Disease | 1 | 1988 | 658 | 0.000 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 1988 | 348 | 0.000 |
Why?
|